ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Mereo BioPharma Group PLC

Mereo BioPharma Group PLC (MREO)

3.30
0.30
(10.00%)
Closed March 29 04:00PM
3.35
0.05
(1.52%)
After Hours: 07:39PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
3.35
Bid
3.26
Ask
3.35
Volume
2,282,523
3.05 Day's Range 3.45
0.688 52 Week Range 4.36
Market Cap
Previous Close
3.00
Open
3.10
Last Trade
1
@
3.34
Last Trade Time
Financial Volume
$ 7,546,813
VWAP
3.3063
Average Volume (3m)
1,827,589
Shares Outstanding
140,176,617
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About Mereo BioPharma Group PLC

Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with ad... Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with advanced solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
London, Gbr
Founded
1970
Mereo BioPharma Group PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MREO. The last closing price for Mereo BioPharma was $3. Over the last year, Mereo BioPharma shares have traded in a share price range of $ 0.688 to $ 4.36.

Mereo BioPharma currently has 140,176,617 shares outstanding.

MREO Latest News

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively...

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference

LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (โ€œMereoโ€ or the โ€œCompanyโ€), a clinical-stage biopharmaceutical company focused on rare diseases, today...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.278.766233766233.083.452.85911255852.97035152CS
4-0.45-11.84210526323.84.072.85912546283.36131562CS
120.9640.16736401672.394.362.2518275893.44480644CS
262148.1481481481.354.361.0715285232.73504816CS
522.5786334.2753435310.77144.360.68814933751.98525785CS
156-0.21-5.898876404493.564.360.30114769641.78943094CS
260-3.2-48.85496183216.556.56590.30111511102.15082927CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

MREO Discussion

View Posts
Monksdream Monksdream 3 days ago
MREO 10Q due 3/27
๐Ÿ‘๏ธ0
Carjockey2 Carjockey2 2 weeks ago
LMAO

Responding to this post???

Not sure why you keep posting to me on this stock I've never been in it..

Hey thanks
๐Ÿ‘๏ธ0
stocksrising stocksrising 2 weeks ago
Fireside chat at 11:20am (est.)โ€ฆstay tuned
๐Ÿ‘๏ธ0
Carjockey2 Carjockey2 2 months ago
Not sure why you keep posting to me on this stock I've never been in it..

Hey thanks
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 2 months ago
Watch and learn as we approach 5 bucks
๐Ÿ‘๏ธ0
Monksdream Monksdream 2 months ago
MREO new 52 week high
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 2 months ago
WATCH AND LEARN
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 2 months ago
MREO...CAN'T HURT THIS STOCK!!!!
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 2 months ago
MREO..THE HOTTEST BIO OUT THERE
๐Ÿ‘๏ธ0
esi23 esi23 3 months ago
Thatโ€™s a real big boy. Lmao.
๐Ÿ‘๏ธ0
esi23 esi23 3 months ago
Should drop to the 20 day @1.96. Run donโ€™t walk out this piggy
๐Ÿ‘๏ธ0
stocksrising stocksrising 3 months ago
I like it, but when it goes thru that, $5โ€™s & $6โ€™s by end of Q1 after some readouts!!( look at 5yr chart)
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 3 months ago
2.97 WEEKLY RESISTANCE BY EOM
๐Ÿ‘๏ธ0
stocksrising stocksrising 3 months ago
Do we break $3 by e.o.m???
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 3 months ago
Fake grandchildren are so adorable
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 3 months ago
You donโ€™t trade real stocks for some odd reason, lolโ€ฆI know why fake granny, so you may fool all the stupid men on this site, but most men are pathetic and easy to lie to.
๐Ÿ‘๏ธ0
Carjockey2 Carjockey2 3 months ago
I'm not even trading this I'm not even sure why he's posting to me and like I said I could give him fat frogs ass what he says to me..

Lol
๐Ÿ‘๏ธ0
stocksrising stocksrising 3 months ago
Iโ€™m gonna stay out of this โ€˜loveโ€™ affair and just say that technically, โ€˜fundamentallyโ€™ and the fact that we have Whales in this ticker, $5 is realistic in 2024!! GLTA ( especially U2, lol) :)
๐Ÿ‘๏ธ0
Carjockey2 Carjockey2 3 months ago
Why are you posting to me I don't give a shit..

LMAO clients

Go lie on another border to somebody else.

๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 3 months ago
MY CLIENTS HOLD 5000 SHARES EACH AT 1.13 THATS HOW THE BIG BOYS PLAY
๐Ÿ‘๏ธ0
Carjockey2 Carjockey2 3 months ago
Oh I believe you so does all of ihub with your credible reputation..

Lolzzzzzz
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 3 months ago
IT WAS SO HARD TO KEEP QUIET...LOL
๐Ÿ‘๏ธ0
Carjockey2 Carjockey2 3 months ago
Lolzzzzzzzzz

๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 3 months ago
WAITING FOR THIS DAY A LONG TIME....LMAO...LOOK BELOW...2.52...MASTER ALWAYS GIVES NUMBERS
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 4 months ago
LOSS....THINK U HAVE LOST YOUR MARBELS...LONG AND STRONG GRANNY!
๐Ÿ‘๏ธ0
Carjockey2 Carjockey2 4 months ago
This is how the big boys play???

Lolzzzz
๐Ÿ‘๏ธ0
Carjockey2 Carjockey2 4 months ago
Who cares moron a loss is a loss great call..

Lolzzzzzzzzz
๐Ÿ‘๏ธ0
Carjockey2 Carjockey2 4 months ago
Huh closed $2.08

Is this how the big boys play??

Lol
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 4 months ago
MREO...GETTING VERY CLOSE TO THE RUMBLE IN THE JUNGLE WITH THAT 2.52 TARGET UP A HEAD
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 5 months ago
REMEMBER THE BUY OUT NEWS 2 YEARS AGO...Make me think theres an offer on the table!
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 5 months ago
MREO...2.35 TRIGGER IN AND NOW 2.52 IS NEXT
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 5 months ago
MREO READY FOR 2.52
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 5 months ago
MREO...HERE WE GO!
💩 1 🤡 1
TrendTrade2016 TrendTrade2016 5 months ago
MREO...BREAKING OUT
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 5 months ago
MREO...2.52 COMING UP!!
๐Ÿ‘๏ธ0
stocksrising stocksrising 5 months ago
Sweet, and more readouts on other P2/3 in pipeline
👍️ 1
TrendTrade2016 TrendTrade2016 5 months ago
MREO BACK IN PLAY ON THE WEEKLY BREAK OUT
🖕 1 🤡 1
TrendTrade2016 TrendTrade2016 5 months ago
wow, nice...shit don't own it
๐Ÿ‘๏ธ0
subslover subslover 5 months ago
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD)

Ultragenyx hosting Analyst Day on Monday, October 16 at 8:30 a.m. ET

NOVATO, Calif., VANCOUVER, British Columbia and LONDON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) today announced interim data from the Phase 2 portion of the Phase 2/3 Orbit study demonstrating that treatment with setrusumab (UX143) significantly reduced incidence of fractures in patients with OI with at least 6 months of follow-up and continues to demonstrate ongoing and meaningful improvements in lumbar spine bone mineral density (BMD). The data were presented in a late-breaker presentation at the American Society for Bone and Mineral Research 2023 Annual Meeting (ASBMR).

As of the cut-off date and following at least 6 months of treatment with setrusumab, the annualized fracture rate across all 24 patients in the Phase 2 portion of the study was reduced by 67%. In the 2 years prior to treatment with setrusumab all patients experienced at least 1 fracture. The median annualized fracture rate of 0.72 in the 2 years prior to treatment was reduced to 0.00 (n=24, p=0.042) during the mean treatment duration period of 9 months. Following initiation of treatment with setrusumab, 20 patients experienced no radiographic-confirmed fractures, and 4 patients experienced 7 radiographic-confirmed fractures in 5 separate events. These fractures exclude fractures of the fingers, toes, skull, and face consistent with the Phase 3 study design.

โ€œI have not yet encountered a patient with a fragility fracture while on setrusumab, and this may result from setrusumabโ€™s effects on the skeleton, improving the rate of new bone formation and bone quality,โ€ said Gary Gottesman, M.D., Professor of Pediatrics and Medicine, Washington University School of Medicine. โ€œSome of the kids feel well enough they are participating in activities that they might normally avoid and have suffered some relatively minor fractures.โ€

The reduction in annualized fracture rates was associated with a clinically meaningful increase in BMD. At the 6-month timepoint, treatment with setrusumab resulted in a mean increase in lumbar spine BMD from baseline of 13% at 20 mg/kg (n=11) and 16% at 40 mg/kg (n=8), which represents the same substantial mean improvement in Z-score of +0.85 for both dose groups at 6 months compared to a combined mean baseline Z-score of โ€“1.68. The small apparent difference in BMD change from baseline is likely related to differences in patients assigned to the two treated groups. There was no statistically significant difference in BMD percent change or Z-score change from baseline between the 20 and 40 mg/kg dosing cohorts.

โ€œThese data provide compelling evidence that improved bone mineral density, resulting from this unique mechanism of action, reduced the risk of fractures and that treatment with setrusumab could allow patients with OI to lead much more active lives with fewer fractures,โ€ said Eric Crombez, M.D., chief medical officer at Ultragenyx. โ€œI want to acknowledge the OI community and especially thank the people living with OI and their caregivers who have aided the setrusumab development program so that we may potentially offer the first approved treatment option for this severe and disabling disease.โ€

As of the data cut-off, there were no treatment-related serious adverse events observed in the study. Reported adverse events were generally consistent with those observed in the ASTEROID study with infusion-related events and headache determined to be the most common adverse events related to the study drug. There have been no reported hypersensitivity reactions related to setrusumab. There were no notable safety-related differences observed between dosing groups or age groups.

The Phase 3 portion of the study is currently enrolling approximately 195 patients at 50 sites across 12 countries.

U.S. residents can learn more by visiting ultraclinicaltrials.com.

Analyst Day and Webcast Information

Ultragenyx will host an Analyst Day at 8:30 a.m. ET on Monday, October 16, 2023 to discuss these data and to provide an update on the companyโ€™s development pipeline. A live video webcast of the program will be available at https://www.webcaster4.com/Webcast/Page/359/49192.
An archived version of the remarks will also be available through the Ultragenyx website.

The Setrusumab Phase 3 Program

The global, seamless Phase 2/3 Orbit study is evaluating the effect of setrusumab on clinical fracture rate in patients aged 5 to
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 7 months ago
MREO by by 1.60s. Hello 1.70s.
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 7 months ago
NEXT STOP 1.85
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 7 months ago
SHORTS WORKED THE TOP AND WENT SHORT 590 000..... WHILE COVERING OVER 400 000 SHARES...THE 1,7 MILLION VOLUME SHARES REPRESENT OVER 1 MILLION SHARES BOUGHT AND SOLD BY RETAIL.
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 7 months ago
MREO....NICE SHAKE TO GET RID OF THE NELLIES AS WE APPROACH LIFT OFF...GAPPING IN PRE!!!
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 7 months ago
HERE WE GO...1.70S HITTING
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 7 months ago
WHEN THE BAKER BROS INVEST IN A STOCK, YA BETTER HOP ON.On July 31, 2023, BAKER BROS. ADVISORS LP purchased 14,604,391 shares of Mereo BioPharma Group PLC at a price of $1.33 per share. This transaction had an impact of 0.11 on the firm's portfolio. Following this acquisition, BAKER BROS. ADVISORS LP now holds a total of 14,604,391 shares in Mereo BioPharma Group PLC, representing 2.20% of the company's total shares...
๐Ÿ‘๏ธ0
tchalla tchalla 7 months ago
ohhhh, you know what down lo is. you are about that life. don't play coy.
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 7 months ago
keep watching...its about to fly!!!
๐Ÿ‘๏ธ0
tchalla tchalla 7 months ago
ohhhh, you know what down lo is. you are about that life. don't play coy.
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 7 months ago
what kind of English is that, you said you went to college..lol...watch and learn how its done!!
๐Ÿ‘๏ธ0
tchalla tchalla 7 months ago
you are the really dummy, bozo the repressed and down lo.
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock